News summaryNovocure investor relationsNov 9, 2026, 12:00 PM
Novocure receives FDA “Not Approvable” letter for Optune Mya brain-metastases application
NVCRregulatory_action
On November 9, 2026, Novocure said FDA declined its PMA application for Optune Mya in adults with NSCLC brain metastases following stereotactic radiation, citing uncertainty about clinical benefit, not safety. The company said it plans to meet with FDA. This is relevant sector regulatory news, not an Alpha Tau action.